亚太地区脑癌诊断市场预测至 2028 年 - COVID-19 影响和按诊断类型(影像测试、腰椎穿刺、活检、分子测试等)进行的区域分析;癌症类型(听神经瘤、星形细胞瘤、颅咽管瘤、神经节神经瘤、多形性胶质母细胞瘤、脑膜瘤、室管膜瘤等);最终用户(医院、专科诊所、门诊手术中心等)

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 159    |    Report Code: TIPRE00025896    |    Category: Life Sciences

Asia Pacific Brain Cancer Diagnostics Market

市场介绍

脑癌是由于大脑中导致肿瘤的细胞在细胞外生长而引起的。肿瘤包括原发性脑肿瘤和继发性脑肿瘤。原发性脑肿瘤在大脑中形成,不会扩散到身体其他部位,而继发性肿瘤,也称为转移瘤,是那些始于身体其他部位的癌症。脑肿瘤分为40种主要类型,进一步分为两大类,包括良性(即生长缓慢且不易扩散)和恶性(即癌变且更容易扩散)。

< p>因此,脑癌患病率的增加预计将在未来几年对脑癌诊断产生巨大需求,预计这将进一步推动脑癌诊断市场的发展。

疫情严重影响了脑癌诊断的发展。影响了亚太地区的医疗旅游业并造成供应链中断;此外,由于医疗基础设施短缺、医院对供应商施加限制、脑癌诊断设备需求下降等,低收入国家面临更多挑战。韩国、马来西亚、新加坡、菲律宾和印度已采取限制措施,以防止疾病传播。预计这些限制性措施将影响这些国家的供应链和医疗器械的供应。它影响了可支配收入,还导致失业。此外,收购、合并和合作等业务战略也会受到全面封锁的不利影响。商业活动中的此类障碍预计将阻碍各种技术先进的医疗保健系统的采用,包括脑癌诊断。

 

市场概况和动态

亚太地区脑癌诊断市场预计将从 2021 年的 1.786 亿美元增长到 1.786 亿美元到 2028 年将达到 5.514 亿;预计 2021 年至 2028 年复合年增长率为 17.5%。“原发性脑肿瘤”一词是指始于大脑的肿瘤。脑部和神经系统癌症是男性和女性第十大死因。在人的一生中,患这种肿瘤的几率不到 1%。大多数原发性中枢神经系统 (CNS) 恶性肿瘤是脑肿瘤,占所有病例的 85% 至 90%。脑肿瘤可能致命,严重影响生活质量,并最终改变患者及其家人的生活。此外,肿瘤的早期发现通常可以提供更多的治疗选择。先进的成像技术可以精确定位脑肿瘤的位置。诊断工具包括磁共振成像 (MRI) 和计算机断层扫描(CT 或 CAT 扫描)。术中 MRI 还可用于指导手术期间的组织活检和肿瘤切除。磁共振波谱(MRS)用于检查肿瘤的化学特征。因此,脑癌患病率的增加迫切需要脑癌诊断工具。      

 

主要细分市场

就诊断类型而言,影像测试细分市场在2020年亚太脑癌诊断市场中占据最大份额。就癌症类型而言,多形性胶质母细胞瘤细分市场在2020年亚太脑癌诊断市场中占据最大份额2020年。就最终用户而言,医院细分市场在2020年亚太脑癌诊断市场中占据最大份额。

 

主要来源和上市公司

准备本脑癌报告时参考的一些主要一手和二手来源亚太地区的诊断市场包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司包括 Thermo Fisher Scientific Inc.、Siemens Healthineers A、GE Healthcare、Biocept, Inc.、Koninklijke Philips NV、Canon Medical Systems、Hitachi, Ltd. 和 Neusoft Medical Systems。

 

原因购买报告

  • 了解亚太地区脑癌诊断市场格局并确定最有可能保证丰厚回报
  • 了解亚太脑癌诊断市场不断变化的竞争格局,保持领先地位
  • 有效规划亚太脑癌诊断领域的并购和合作交易通过识别最有前景的可能销售的细分市场来确定市场
  • 通过对亚太脑癌诊断市场各个细分市场的市场表现进行敏锐和全面的分析,帮助做出明智的业务决策
  • 获得亚太地区2021-2028年各细分市场的市场收入预测

 

亚太地区脑癌诊断市场细分      

 

按诊断类型

  • 影像学检查
    • MRI< /li>
    • CT扫描
    • PET
  • 活检
  • 分子检测
  • 腰椎穿刺
  • 其他

 

按癌症类型

< ul>
  • 多形性胶质母细胞瘤
  • 星形细胞瘤
  • 室管膜瘤
  • 其他
  •  

    最终用户

    • 医院
    • 专科诊所
    • < li>门诊手术中心
    • 其他

     

    按国家/地区

      < li>亚太地区
      • 中国
      • 日本
      • 印度
      • 韩国
      • 澳大利亚
      • 亚太地区其他地区

     

    提及的公司

    1. Thermo Fisher Scientific Inc.
    2. Siemens Healthineers A
    3. GE Healthcare
    4. Biocept, Inc. .
    5. Koninklijke Philips NV
    6. 佳能医疗系统
    7. 日立有限公司
    8. 东软医疗系统

     

     

     

    Asia Pacific Brain Cancer Diagnostics Strategic Insights

    Strategic insights for Asia Pacific Brain Cancer Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

    strategic-framework/asia-pacific-brain-cancer-diagnostics-market-strategic-framework.webp
    Get more information on this report

    Asia Pacific Brain Cancer Diagnostics Report Scope

    Report Attribute Details
    Market size in 2021 US$ 178.6 Million
    Market Size by 2028 US$ 551.4 Million
    Global CAGR (2021 - 2028) 17.5%
    Historical Data 2019-2020
    Forecast period 2022-2028
    Segments Covered By 诊断类型
    • 影像学检查
    • 腰椎穿刺
    • 活检
    • 分子检测
    By 癌症类型
    • 听神经瘤
    • 星形细胞瘤
    • 颅咽管瘤
    • 神经节细胞瘤
    • 多形性胶质母细胞瘤
    • 脑膜瘤
    • 室管膜瘤
    By 最终用户
    • 医院
    • 专科诊所
    • 门诊手术中心
    Regions and Countries Covered 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
    Market leaders and key company profiles
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers A
  • GE Healthcare
  • Biocept, Inc.
  • Koninklijke Philips N.V
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Neusoft Medical Systems
  • Get more information on this report

    Asia Pacific Brain Cancer Diagnostics Regional Insights

    The regional scope of Asia Pacific Brain Cancer Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-brain-cancer-diagnostics-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Brain Cancer Diagnostics Market

    1. Thermo Fisher Scientific Inc.
    2. Siemens Healthineers A
    3. GE Healthcare
    4. Biocept, Inc.
    5. Koninklijke Philips N.V
    6. Canon Medical Systems
    7. Hitachi, Ltd.
    8. Neusoft Medical Systems
    Frequently Asked Questions
    How big is the Asia Pacific Brain Cancer Diagnostics Market?

    The Asia Pacific Brain Cancer Diagnostics Market is valued at US$ 178.6 Million in 2021, it is projected to reach US$ 551.4 Million by 2028.

    What is the CAGR for Asia Pacific Brain Cancer Diagnostics Market by (2021 - 2028)?

    As per our report Asia Pacific Brain Cancer Diagnostics Market, the market size is valued at US$ 178.6 Million in 2021, projecting it to reach US$ 551.4 Million by 2028. This translates to a CAGR of approximately 17.5% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Brain Cancer Diagnostics Market report typically cover these key segments-

  • 诊断类型 (影像学检查, 腰椎穿刺, 活检, 分子检测)
  • 癌症类型 (听神经瘤, 星形细胞瘤, 颅咽管瘤, 神经节细胞瘤, 多形性胶质母细胞瘤, 脑膜瘤, 室管膜瘤)
  • 最终用户 (医院, 专科诊所, 门诊手术中心)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Brain Cancer Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Brain Cancer Diagnostics Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Brain Cancer Diagnostics Market?

    The Asia Pacific Brain Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers A
  • GE Healthcare
  • Biocept, Inc.
  • Koninklijke Philips N.V
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Neusoft Medical Systems
  • Who should buy this report?

    The Asia Pacific Brain Cancer Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Brain Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.